NCT06313047

Pharmacogenetic of Doxorubicin in HCC.

Pharmacogenetic of Doxorubicin in Patients With Hepatocellular Carcinoma: A Prospective Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 81 (actual)
• Sponsor: Rehab Werida · Academic / Other
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: —

Summary

The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.

Detailed description

All patients had their baseline viral indicators for HBV and HCV evaluated. Additionally, blood samples were taken for genotyping. All patients underwent evaluations of their kidney, liver, and alpha fetoprotein (AFP) functions, as well as their complete blood count (CBC), at both the baseline and follow-up appointments. To evaluate the efficacy of TACE, triple pelvic abdominal CT scans were performed both prior to and one month later. Using triphasic pelviabdominal CT, patients who achieved complete response (CR) were monitored for up to 13 months following chemotherapy in order to identify recurrence. Follow-up appointments were planned to identify patients responces or any negative effects.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Doxorubicin	each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.

Timeline

• Start date: 2021-01-01
• Primary completion: 2023-12-15
• Completion: 2023-12-30
• First posted: 2024-03-15
• Last updated: 2024-03-28

Locations

1 site across 1 country: Saudi Arabia